RT Journal Article
T1 Biological treatments in Behçet's disease: beyond anti-TNF therapy.
A1 Caso, Francesco
A1 Costa, Luisa
A1 Rigante, Donato
A1 Lucherini, Orso Maria
A1 Caso, Paolo
A1 Bascherini, Vittoria
A1 Frediani, Bruno
A1 Cimaz, Rolando
A1 Marrani, Edoardo
A1 Nieves-Martín, Laura
A1 Atteno, Mariangela
A1 Raffaele, Carmela G L
A1 Tarantino, Giusyda
A1 Galeazzi, Mauro
A1 Punzi, Leonardo
A1 Cantarini, Luca
K1 Anticuerpos monoclonales humanizados
K1 Síndrome de behçet
K1 Interleucina 1
K1 Interleucina-1beta
K1 Interleucina-6
K1 Factor necrosis tumoral alfa
AB Behçet's disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to protean inflammatory involvement of multiple organs and tissues. Treatment has been revolutionized by the progressed knowledge in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1β, and IL-6. However, although biological treatment with anti-TNF-α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time. Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. Different agents targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and the B-lymphocyte antigen CD-20 by rituximab. The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF-α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium.
PB Hindawi Publishing Corporation
SN 0962-9351
YR 2014
FD 2014-06-30
LK http://hdl.handle.net/10668/2025
UL http://hdl.handle.net/10668/2025
LA en
NO Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, et al. Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm.; 2014:107421
NO Journal Article; Review;
DS RISalud
RD Apr 7, 2025